Ovid Therapeutics Inc. (NASDAQ: OVID) is a Healthcare company (Biotechnology) with a market capitalization of $419M. The Maz Rating grades it against the other companies in its sector.
Ovid Therapeutics Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.22, Ovid Therapeutics Inc. trades at 284.9x sales and 2.2x book value. Over the last twelve months it generated about $1M of revenue and a net loss of $34M. It runs an operating margin of -4700.3% and a net margin of -2971.3%. It shows return on equity of -23.4%, return on invested capital of -32.2% and a free cash flow yield of -13.8%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 11.97. Over the past 52 weeks the share price ranged from $1.21 to $3.11, with a beta of 0.24.
Ovid Therapeutics Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 11 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.